#34 – Junin Virus: a 30 Percent Fatality Rate, but There's a Vaccine

Junin virus causes Argentine hemorrhagic fever, a disease with a case fatality rate of 20 to 30 percent. Florian Krammer explains why these New World arenaviruses are named after sand (they package host cell ribosomes that look like grains of sand under the electron microscope) and what makes their spike protein unusual: the signal peptide stays part of the glycoprotein complex, something found nowhere else in biology. The virus is carried by field mice, mainly the dryland vesper mouse, and people usually get infected by inhaling dust from dried urine and feces. That's why it mostly affects men working in agriculture, with over 90 percent of the 300 to 500 annual cases occurring in rural areas. Unlike most hemorrhagic fevers, this one has countermeasures: the live attenuated vaccine Candid One with 95 percent efficacy, and convalescent plasma that cuts fatality to one or two percent but causes late neurological symptoms in about 8 to 10 percent of patients. Florian Krammer's own lab is about to publish monoclonal antibodies that could replace plasma therapy. Information about Junin virus and Argentine hemorrhagic fever from the UK Health Security Agency: https://www.gov.uk/guidance/argentine-haemorrhagic-fever-origins-reservoirs-transmission-and-guidelines New paper about Junin virus monoclonal antibodies that could be used for treatment: https://journals.asm.org/doi/10.1128/mbio.00214-26 +++++ You can support the podcast via our German Steady page: https://steady.page/virologisch/ Questions, feedback or topic suggestions? Feel free to contact us at: virological@podcastwerkstatt.com +++++ Krammer laboratory information Krammer Laboratory at the Icahn School of Medicine at Mount Sinai https://labs.icahn.mssm.edu/krammerlab/ Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness https://soap.lbg.ac.at/ Ignaz Semmelweis Institute https://semmelweisinstitute.ac.at/ +++++ Conflict of interest statement The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines and therapeutics, SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which name me as inventor. Mount Sinai has spun out a company, CastleVax, to commercialize NDV-based SARS-CoV-2 vaccines and I am named as co-founder and scientific advisory board member of that company. I have previously consulted for Curevac, Merck, Gritstone, Sanofi, Seqirus, GSK and Pfizer and I am currently consulting for 3rd Rock Ventures (US) and Avimex (Mexico). My laboratory has been collaborating in the past with Pfizer on animal models of SARS-CoV-2 and with GlaxoSmithKline and VIR on the development of influenza virus vaccines and therapeutics and we are currently collaborating with Dynavax, Inspirevax and Inimmune on development of influenza virus vaccines. My work in the on immunity and infectious diseases in the US is supported by the National Institutes of Health, but also by FluLab and Tito’s Handmade Vodka. In the past I have also received funding from the Bill and Melinda Gates Foundation, PATH and the US Department of Defense. My work in Austria is supported by the Ludwig Boltzmann Gesellschaft and by the Ignaz Semmelweis Institute through the Medical University of Vienna.